Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($3.09), $0.65 better than the analyst estimate of ($3.74). Revenue for the quarter came in at $27 million versus the consensus estimate of $25.91 million.

2017 Guidance

For the year ending December 31, 2017, the Company’s financial guidance is as follows:

• GAAP sales are estimated to be in the range of $100 million to $105 million; non-GAAP sales are estimated to be in the range of $95 million to $100 million
• GAAP operating margin is estimated to be in the range of negative 65 percent to negative 60 percent; non-GAAP operating margin is estimated to be in the range of negative 70 percent to negative 65 percent, both of which include:
  • Approximately $12.0 million in non-cash, stock-based compensation expense
  • Approximately $5.0 million to $6.0 million of depreciation and amortization

GUIDANCE:

Tandem Diabetes sees FY2017 revenue of $95-100 million, versus the consensus of $101.96 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.